Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 1:57 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 6,446 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Kidney Clear all
Completed Phase 4 Interventional Results available

Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5

NCT02392208
View directory record Official record
Conditions
End-Stage Renal Disease, Stage 5 Chronic Kidney Disease
Interventions
Telavancin, Pharmacokinetic Blood Sampling
Drug · Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Nov 3, 2026, 1:57 PM EST
Completed Phase 3 Interventional

Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium

NCT00003376
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
carboplatin, cisplatin, doxorubicin hydrochloride, methotrexate, paclitaxel, vinblastine
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
50
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Nov 3, 2026, 1:57 PM EST
Terminated Not applicable Interventional Results available

The Efficacy of "MediHoney" to Facilitate Catheter Exit-Site Surgical Wound Healing

NCT01230489
View directory record Official record
Conditions
Renal Failure
Interventions
MediHoney
Biological
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 90 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Nov 3, 2026, 1:57 PM EST
Recruiting No phase listed Observational

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

NCT03452774
View directory record Official record
Conditions
Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver, Cancer of Stomach, Cancer Liver, Cancer of Rectum, Cancer of Kidney, Cancer of Esophagus, Cancer of Cervix, Cancer of Colon, Cancer of Larynx, Cancer, Lung, Cancer, Breast, Cancer, Advanced, Cancer Prostate, Cancer of Neck, Cancer of Skin, Neuroendocrine Tumors, Carcinoma, Mismatch Repair Deficiency, BRCA Gene Rearrangement, Non Hodgkin Lymphoma, Leukemia, Non Small Cell Lung Cancer, Cholangiocarcinoma, Glioblastoma, Central Nervous System Tumor, Melanoma, Urothelial Carcinoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Testicular Cancer, Breast Cancer, COVID, Myelofibrosis, Myeloproliferative Neoplasm, Myeloproliferative Disorders, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndromes
Interventions
Clinical Trial Matching
Other
Lead sponsor
Massive Bio, Inc.
Industry
Eligibility
Not listed
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2040
U.S. locations
67
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Nov 3, 2026, 1:57 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia

NCT04380610
View directory record Official record
Conditions
Sickle Cell Disease, Renal Disease, Glomerular Disease
Interventions
iohexol GFR
Diagnostic Test
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
5 Years to 50 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
4
States / cities
Birmingham, Alabama • Chicago, Illinois • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Nov 3, 2026, 1:57 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Natural Protein vs. Protein Supplements on Peritoneal Dialysis Patients

NCT03569410
View directory record Official record
Conditions
Peritoneal Dialysis Complication, Hypoalbuminemia, Malnutrition
Interventions
increased protein intake via natural foods, increase protein intake via protein supplements
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Nov 3, 2026, 1:57 PM EST
Withdrawn Not applicable Interventional

Ambulatory Versus Inpatient Percutaneous Nephrolithotomy

NCT04690010
View directory record Official record
Conditions
Kidney Calculi
Interventions
Ambulatory tubeless PCNL, Inpatient PCNL with nephrostomy tube
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 3, 2026, 1:57 PM EST
Completed Phase 2 Interventional Results available

Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer

NCT01835158
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
Interventions
Cabozantinib S-malate, Laboratory Biomarker Analysis, Sunitinib Malate
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
488
States / cities
Mobile, Alabama • Anchorage, Alaska • Burbank, California + 295 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Nov 3, 2026, 1:57 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)

NCT05468697
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Belzutifan, Palbociclib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Nov 3, 2026, 1:57 PM EST
Recruiting Not applicable Interventional

Lupus Nephritis Care Pathway

NCT07783152
View directory record Official record
Conditions
Lupus Nephritis (LN)
Interventions
Lupus Nephritis (LN) Care Pathway
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 3, 2026, 1:57 PM EST
Terminated Phase 4 Interventional Results available

Once Daily Immunosuppression Regimen

NCT03555448
View directory record Official record
Conditions
Kidney Transplant; Complications
Interventions
Once daily immunosuppression regimen, Twice daily immunosuppression regimen
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Nov 3, 2026, 1:57 PM EST
Completed Not applicable Interventional

Saline Against Lactated Ringers or Plasmalyte in the Emergency Department

NCT02614040
View directory record Official record
Conditions
Critical Illness, Acute Kidney Injury
Interventions
0.9% Saline, Physiologically-balanced isotonic crystalloid
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
14,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Nov 3, 2026, 1:57 PM EST
Completed Phase 2 Interventional Results available

Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

NCT05834738
View directory record Official record
Conditions
IgA Nephropathy, Immunoglobulin A Nephropathy
Interventions
Atrasentan, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Birmingham, Alabama • Atlanta, Georgia • Oak Brook, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Nov 3, 2026, 1:57 PM EST
Completed Not applicable Interventional

Kaiser Permanente Evaluation of Medically Tailored Meals in Adults With Medical Conditions at High Readmission Risk

NCT05166525
View directory record Official record
Conditions
Heart Failure, Chronic Kidney Diseases, Diabetes Mellitus, Type 2
Interventions
Medically tailored meals
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Oakland, California • San Francisco, California • San Rafael, California + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2021 · Synced Nov 3, 2026, 1:57 PM EST
Completed Phase 2 Interventional Results available

Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine

NCT03527238
View directory record Official record
Conditions
Liver Transplant, Kidney Transplant
Interventions
PPM-based Computation Assisted Drug Dosing, Tacrolimus
Other · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Los Angeles, California • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2021 · Synced Nov 3, 2026, 1:57 PM EST
Completed Phase 2 Interventional

Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury

NCT01146925
View directory record Official record
Conditions
Contrast-Induced Acute Kidney Injury
Interventions
CRMD-001-Deferiprone, Placebo
Drug
Lead sponsor
CorMedix Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Indianapolis, Indiana • Detroit, Michigan • Petoskey, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Nov 3, 2026, 1:57 PM EST
Active, not recruiting Not applicable Interventional

A Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities

NCT05321368
View directory record Official record
Conditions
Hypertension, High Blood Pressure, Diabetes, Chronic Kidney Diseases
Interventions
LINKED-HEARTS Program
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Denton, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 3, 2026, 1:57 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers

The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes

NCT00044148
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
LY333531
Drug
Lead sponsor
Chromaderm, Inc.
Industry
Eligibility
30 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
15
States / cities
La Jolla, California • Walnut Creek, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Nov 3, 2026, 1:57 PM EST
Completed Not applicable Interventional Results available

Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome

NCT01113385
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Steroid Resistant Nephrotic Syndrome
Interventions
D-Galactose
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
2 Years to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Nov 3, 2026, 1:57 PM EST
Active, not recruiting Not applicable Interventional

MITIGAAT: Multifaceted Intervention To Improve Graft Outcome Disparities in African American Kidney Transplants

NCT06023615
View directory record Official record
Conditions
Medication Adherence, Medication Compliance
Interventions
mHealth app/dashboard
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Nov 3, 2026, 1:57 PM EST
Recruiting No phase listed Observational

The Effects of the CF Carrier State on the Kidneys and Pancreas

NCT05474417
View directory record Official record
Conditions
Carrier State, Pancreatic Disease, Kidney Diseases
Interventions
Not listed
Lead sponsor
Philip Polgreen
Other
Eligibility
18 Years to 100 Years
Enrollment
1,250 participants
Timeline
2021 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 3, 2026, 1:57 PM EST
Completed Phase 1Phase 2 Interventional Results available

Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant

NCT00670774
View directory record Official record
Conditions
Kidney Transplant
Interventions
Eculizumab
Drug
Lead sponsor
Mark Stegall
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Nov 3, 2026, 1:57 PM EST
Active, not recruiting Phase 3 Interventional

Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

NCT05138133
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Anifrolumab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
16
States / cities
Glendale, Arizona • La Palma, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 3, 2026, 1:57 PM EST
Recruiting Phase 3 Interventional

A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

NCT03619850
View directory record Official record
Conditions
Chronic Kidney Disease; Iron Deficiency Anemia
Interventions
Ferumoxytol, Iron sucrose
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
8
States / cities
Hollywood, Florida • Detroit, Michigan • Kansas City, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Nov 3, 2026, 1:57 PM EST